Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 56Recruiting 54Completed 18Not yet recruiting 16Terminated 7Withdrawn 2Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Specimen Handling 35Magnetic Resonance Spectroscopy 23Biopsy 22Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Taxes 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4X-Rays 4Vincristine 4Surgical Procedures, Operative 4Radiosurgery 4Radiation 4Gemcitabine 4Doxorubicin 4Cetuximab 4130-nm albumin-bound paclitaxel 4durvalumab 3decitabine and cedazuridine drug combination 3cemiplimab 3Tacrolimus 3Surveys and Questionnaires 3Radiotherapy, Intensity-Modulated 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × daratumumab × 1 year × Clear all
NCT06348147 2026-05-04

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

UNC Lineberger Comprehensive Cancer Center

Phase 2 Suspended
39 enrolled
Plasma cell

Multiple Myeloma

NCT04661137 2026-02-10

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Hackensack Meridian Health

Phase 2 Suspended
96 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡